Friday, 10 July 2009

Pioglitazone Hydrochloride (Actos) 15, 30 and 45 mg tablets: Innovator Takeda sued generic player

Innovator Takeda Pharma has sued Indian generic player Torrent Pharma in U.S. District Court for the Southern District of New York in a bid to block generic challenge on Pioglitazone Hydrochloride (Actos) 15, 30 and 45 mg tablets. Innovator Takeds in it’s complaint has asserted six patents against Torrent and has requested court to block generic approval till (June, 2016) expiry of asserted patents.

Earlier, innovator Takeda has successfully defended the invalidation bid of generic players against it’s key patent (product patent) US4687777 (Expiry: JAN 17,2011) by generic players Alphapharm and Mylan as reported by us Here and Here

Innovator Takeda got approval to market this product from USFDA on Jul 15, 1999.

For complete story please check article published in Bloomberg Here

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker